TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
ONC
businesswire.comMarch 4, 2025
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company planning to change its name to BeOne Medicines Ltd., has announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) for use with platinum-based chemotherapy. This treatment is for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors show PD-L1 expression (≥1). "The approval of TEVI...
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
ONC
247wallst.comFebruary 28, 2025
If you want to learn about biotechnology stocks, billionaires Julian and Felix Baker are great sources of information.